Hvis du har foretaget ændringer i Pure, vil de snart blive vist her.

Publikationer 1988 2019

Filtrer
Konferenceabstrakt til konference

Immunomodulatory Effects and Adaptive Immune Response to Daratumumab in Multiple Myeloma in Blood, vol. 126, issue 23.

Plesner, T., 3. dec. 2015.

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskningpeer review

Smouldering multiple myeloma risk factors for progression. An analysis of 289 cases in the danish multiple myeloma registry

Sørrig, R., Klausen, T. W., Frølund, U. C., Gregersen, H., Helleberg, C., L. Kristensen, D., Andersen, N. F., Plesner, T., Pulczinsky, S., Albildgaard, N., Mourits-Andersen, T., Clausen, N. T., Vangsted, A., Salomo, M. & Gimsing, P., 2015.

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskningpeer review

2014

An ongoing open-label phase 1/2a study of the safety and efficacy of melphalan-flufenamide (melflufen) and dexamethasone combination for patients with relapsed and relapsed-refractory multiple myeloma

Mellqvist, U-H., Paba-Prada, C., Palumbo, A., Plesner, T., Sonneveld, P., Voorhees, P., Byrne, C., Harmenberg, J., Nordström, E. & Richardson, P., 2014.

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskningpeer review

Determination of the MTD and Encouraging Results in an Ongoing Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination for Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM)

Paba-Prada, C., Palumbo, A., Mellqvist, U-H., Voorhees, P., Plesner, T., Sonneveld, P., Byrne, C., Harmenberg, J., Nordstrom, E. & Richardson, P., 2014.

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskningpeer review

Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM)

Lokhorst, H., Laubach, J., Nahi, H., Plesner, T., Gimsing, P., Hansson, M., Minnema, M., Lassen, U., Krejcik, J., Ahmadi, T., Khan, I., Uhlar, C., Lisby, S., Basse, L., C. Brun, N. & Richardson, P., 2014.

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskningpeer review

Effects of single-agent bortezomib (btz) as post-transplant consolidation on multiple myeloma (MM)-related bone disease: first results from a multicenter, randomized phase 2 study

Sezer, O., Beksac, M., Hajek, R., Sucak, G., Cagirgan, S., Linkesch, W., Meltem Akay, O., Armbrecht, G., Plesner, T., Snowden, J., Nahi, H., Gülbas, Z., Potamianou, A., Couturier, C., Olie, R., Feys, C., Allietta, N. & Terpos, E., 2014.

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskningpeer review

Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)

Eichhorst, B., Fink, A. M., Busch, R., Kovacs, G., Maurer, C., Lange, E., Köppler, H., G Kiehl, M., Soekler, M., Schlag, R., Vehling-Kaiser, U., R. A. Köchling, G., Plöger, C., Gregor, M., Plesner, T., Trneny, M., Fischer, K., Döhner, H., Kneba, M., Wendtner, C-M. & 5 flere, Klapper, W., Kreuzer, K. A., Stilgenbauer, S., Böttcher, S. & Hallek, M., 2014.

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskningpeer review

Randomized Phase III Trial in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma Comparing Melphalan-Prednisone-Thalidomide Followed By Thalidomide Maintenance (MPT-T) Versus Melphalan-Prednisone-Lenalidomide Followed By Maintenance with Lenalidomide (MPR-R); A Joint Study of the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and the Nordic Myeloma Study Group (NMSG)

Zweegman, S., van der Holt, B., Mellqvist, U-H., Salomo, M., M. J. Bos, G., Levin, M-D., A. Visser-Wisselaar, H., Hansson, M., WG van der Velden, A., Deenik, W., Gruber, A., LLM Coenen, J., Plesner, T., K Klein, S., Tanis, B., L. Szatkowski, D., Brouwer, R., Westerman, M., Leys, BL., W. C. J. van de Donk, N. & 8 flere, Haukås, E., van der Hem, K., Durian, MF., Mattijssen, E. V. JM., AM Sinnige, H., JPL Stevens-Kroef, M., Sonneveld, P. & Waage, A., 2014.

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskningpeer review

Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma

Plesner, T., Arkenau, H-T., Lokhorst, H. M., Gimsing, P., Krejcik, J., Rose Lemech, C., Minnema, M., Lassen, U. N., Laubach, J., Ahmadi, T., Yeh, H., Guckert, M., Feng, H., C. Brun, N., Lisby, S., Basse, L., Palumbo, A. & Richardson, P., 2014.

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskningpeer review

Daratumumab, a CD38 mab, for the treatment of relapsed/refractory multiple myeloma patients: Preliminary efficacy data from a multicenter phase I/II study

Lokhorst, H., Plesner, T., Gimsing, P., Nahi, H., Minnema, M., Lassen, U. N., Krejcik, J., Laubach, J., Lisby, S., Basse, L. & Richardson, P., maj 2013.

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskningpeer review

Daratumumab, a CD38 Monoclonal Antibody in Patients With Multiple Myeloma - Data From A Dose-Escalation Phase I/II Study

Plesner, T., Lokhorst, H., Gimsing, P., Nahi, H., Basse, L., Lisby, S. & Richardson, P., apr. 2013.

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskningpeer review

Daratumumab, a CD38 Monoclonal Antibody Study in Advanced Multiple Myeloma – an Open-Label, Dose Escalation Followed by Open-Label Extension in a Single-Arm Phase I/II Study

Lokhorst, H., Plesner, T., Gimsing, P., Nahi, H., Lisby, S. & Richardson, P., jun. 2013.

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskningpeer review

Preliminary Safety and Efficacy Data of Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

GEN503 Study Group, dec. 2013.

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskningpeer review

2012

"Differences and similarities in treatment related effects of zoledronic acid in multiple myeloma and breast cancer patients with metastasis to bone." in Journal of Bone and Mineral Research, 27, suppl.1, p213-S214.

Søe, K., Delaissé, J-M., Hugger Jakobsen, E., Hansen, CT. & Plesner, T., 2012. 2 s.

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskningpeer review

"Is zoledronic acid retention onto bone different in multiple myeloma and breast cancer patients with bone metastasis?" in Journal of Bone and Mineral Research, 27, suppl. 1, p323

Søe, K., Plesner, T., Hugger Jakobsen, E., Hansen, CT., Jørgensen, H. & Delaissé, J-M., 2012. 1 s.

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskningpeer review

Paroxystisk Nokturn Hæmoglobinuri i Danmark

Brieghel, C., Kjeldsen, L. J., Christiansen, I., Nielsen, B., Plesner, T., Vestergaard, H., Kræsten Raaschou Jensen, K., Klausen, T. W. & Birgens, H., 2012.

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskning

2011

A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ≥ 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65-75 Yrs Enrolled in MM-015

Palumbo, A., Adam, Z., Kropff, M., Foà, R., Catalano, J., Gisslinger, H., Wiktor-Jedrzejczak, W., Delforge, M., Weisel, K., Cascavilla, N., Van Droogenbroeck, J., Iosava, G., Cavo, M., Blade, J., Beksac, M., Spicka, I., Plesner, T., Yu, Z., Herbein, L., Mei, J. & 2 flere, Jacques, CJ. & Dimopoulus, MA., dec. 2011.

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskningpeer review

2010

Efficacy of Rituximab in combination with Dexamethasone vs. Dexamethasone in newly diagnosed patients with primary immune thrombocytopenia - an interim analysis of a prospective randomized study

Gudbrandsdottir, S., Frederiksen, H., Rasmussen, I. H., Jensen, B., Kjeldsen, L., Klausen, T., Mourits-Andersen, T., Nielsen, CH., Nielsen, OJ., Plesner, T., Pulczynski, S., Rønnov-Jensen, D., Hasselbalch, HC. & Birgens, H., 2010.

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskningpeer review

2009

Impaired Stem Cell Mobilization by Fludarabinde in MM: Results from a Randomized Phase II Trial

Johnsen, HE., Lennhoff, S., Tangen, Gluud, C., Meldgaard Knudsen, L., Mylin, AK., Gimsing, P., Gregersen, H., Abildgaard, N., Nielsen, JL., Andersen, NF., Plesner, T., Vangsted, AJ., Mourits-Andersen, T. & Mellqvist, UH., 2009.

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskning

Kromosomforandringer påvist med G-bånd karyotypering ved myelomatose

Kerndrup, G. B., Sørensen, A. G., Christensen, J. H., Abildgaard, N., Frederiksen, M., Mourits-Andersen, T. & Plesner, T., 2009.

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskning

Rapid stimulation of bone formation by bortezomib in multiple myeloma

Lund, T., Søe, K., Abildgaard, N., Garnero, P., Pedersen, PT., Delaissé, J-M. & Plesner, T., 2009.

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskning

2007

Cells of the myeloma clone directly contribute to the formation of osteoclasts in myeloma patients

Levin Andersen, T., Boissy, P., Søndergaard, TE., Kupisiewicz, K., Plesner, T., Kølvrå, S. & Delaissé, J-M., 2007.

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskning

Lymphocytic cells from the myloma B-cell clone contribute  to the formation of osteoclasts in myeloma patients

Levin Andersen, T., Boissy, P., Søndergaard, TE., Kupisiewicz, K., Plesner, T., Rasmussen, T., Christensen, J. H., Kølvrå, S. & Delaissé, J-M., 2007.

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskning